Gasbjerg LS, Helsted MM, Hartmann B, Sparre-Ulrich AH, Veedfald S, Stensen S, et al
In published Phase 3 trials, the mean weight loss reported for retatrutide at 80 weeks (28.3%) exceeded the mean reported for tirzepatide in SURMOUNT-1 at 72 weeks (22.5%) [1][2][9]
It never predicts how you will respond to a medication
Multiple animal studies including post-infarction models show Thymosin Beta-4 reduces scar tissue formation, promotes cardiomyocyte survival, and supports microvascular regeneration in damaged heart tissue.22 A 2010 study published in Annals of the New York Academy of Sciences showed that Thymosin Beta-4 initiated adult cardiac progenitor cell differentiation and cardiac repair in injured myocardium.23 While direct long COVID RCT data doesn't yet exist for TB-500, the mechanistic overlap with long COVID cardiovascular pathology is strong
The peptide has a simple structure just three amino acids (glycine, histidine, and lysine) bound to a copper(II) ion